Literature DB >> 21731521

Commentary: role of bone-modifying agents in metastatic breast cancer.

Gabriel N Hortobagyi.   

Abstract

Entities:  

Year:  2011        PMID： 21731521      PMCID： PMC3051858          DOI： 10.1200/JOP.2011.000218

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  12 in total

Review 1.  Molecular biology of bone metastasis.

Authors:  Lauren A Kingsley; Pierrick G J Fournier; John M Chirgwin; Theresa A Guise
Journal:  Mol Cancer Ther       Date:  2007-10       Impact factor: 6.261

Review 2.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

Authors:  R E Coleman
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

3.  Treatment of skeletal disease in breast cancer: a controlled clodronate trial.

Authors:  I Elomaa; C Blomqvist; L Porkka; C Lamberg-Allardt; G H Borgström
Journal:  Bone       Date:  1987       Impact factor: 4.398

4.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

5.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

Authors:  A Lipton; R L Theriault; G N Hortobagyi; J Simeone; R D Knight; K Mellars; D J Reitsma; M Heffernan; J J Seaman
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

Review 6.  Future directions of bone-targeted therapy for metastatic breast cancer.

Authors:  Tomifumi Onishi; Naoki Hayashi; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

7.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Authors:  Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

9.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  Unusual mid-shaft fractures during long-term bisphosphonate therapy.

Authors:  Clarita V Odvina; Shiri Levy; Sudhir Rao; Joseph E Zerwekh; D S Rao
Journal:  Clin Endocrinol (Oxf)       Date:  2009-03-19       Impact factor: 3.478
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.